Brain tumour survival & prognosis in children — what parents need to know

Survival rates for childhood brain tumours vary widely depending on the tumour type, grade, location, and age at diagnosis. Some tumour types — such as low-grade gliomas — carry a very good outlook, with the majority of children achieving long-term survival with appropriate treatment. Others, such as diffuse intrinsic pontine glioma (DIPG), remain very difficult to treat. Population-level statistics are a starting point, not a prediction for your individual child. Your child's oncologist will give you a personalised picture based on the specific type and grade of tumour, the extent of surgery, and how the tumour responds to treatment.

The most important factors are the tumour type and WHO grade (low-grade tumours generally have a more favourable outlook than high-grade ones), the tumour's location in the brain (surgery is easier and safer for tumours in accessible locations), whether the tumour can be completely removed, the child's age at diagnosis, and the specific molecular features of the tumour cells — such as IDH mutation status, H3K27 alteration, or BRAF fusion. These molecular markers are now a routine part of every paediatric brain tumour workup and directly shape the treatment plan.

The most common brain tumours in children include low-grade gliomas (such as pilocytic astrocytoma), medulloblastoma, ependymoma, and diffuse intrinsic pontine glioma (DIPG). Each of these behaves differently, responds differently to treatment, and carries a different prognosis. Low-grade gliomas are often slow-growing and carry a relatively favourable outlook. Medulloblastoma, though aggressive, responds well to surgery plus radiation and chemotherapy in many children. Correct diagnosis — ideally with molecular profiling — is the essential first step before any treatment decision is made.

This page focuses on prognosis, not diagnosis; for a full list of warning signs see our paediatric brain tumour symptoms page. In brief, symptoms that warrant prompt medical evaluation include persistent morning headaches (especially with vomiting), a new squint or change in vision, unexplained balance or walking problems, sudden personality or behaviour changes, a new seizure, or signs of raised intracranial pressure. These symptoms do not necessarily indicate a brain tumour — many have simpler explanations — but they should always be assessed by a doctor without delay. Early imaging when symptoms point to the brain is never an overreaction.

Treatment depends entirely on the tumour type, grade, and location. Surgery is the first step for most accessible tumours — the goal is to remove as much tumour as safely possible without affecting the surrounding healthy brain. After surgery, radiation therapy and/or chemotherapy may be recommended depending on the tumour type and residual disease. For certain molecular subtypes, targeted therapies are now available. For very young children, chemotherapy is often preferred over radiation to protect the developing brain. Every child's case at CION is reviewed by a tumour board that includes a neuro-oncologist, neurosurgeon, radiation oncologist, and paediatric specialist before a treatment plan is confirmed.

Paediatric brain tumours are among the most complex cancers to treat. No single specialist — however skilled — has expertise across neurosurgery, paediatric neuro-oncology, radiation planning, pathology, and molecular diagnostics simultaneously. A tumour board brings all of these specialists together before any treatment is started. At CION Cancer Clinics, every child's case is presented at a dedicated tumour board. This means treatment decisions reflect a genuine multi-specialist consensus — not one doctor's opinion — and the plan is tailored to your child's specific tumour biology, not a standard protocol applied to the average patient.